194014AB2

• Second-quarter 2026 net sales were $583 million, up 3% reported and 5% organic year-over-year.
• Reconstructive segment sales grew 8% reported and 6% organic; P&R declined 1% reported but grew 3% organic.
• Adjusted EBITDA was $104 million, or 17.9% of sales.
• Reaffirmed 2026 guidance: revenue $2.31-2.37 billion, adjusted EBITDA $425-435 million, adjusted EPS $3.52-3.73, free cash flow conversion 25% or higher.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The amendment increases the annual compensation limit for Outside Directors from $350,000 to $750,000, with a 200% limit in the year of initial election or appointment as lead director or chair.
• All ten director nominees were elected, with vote totals ranging from approximately 50.96 million to 51.55 million votes 'for' each.
• Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for 2026, with 52,862,698 votes for.
• The non-binding advisory vote on executive compensation was approved, with 49,531,111 votes for and 2,175,335 against.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• First-quarter 2026 net sales were $589 million, up 5% reported and 3% organic from the prior-year quarter.
• Net loss was $8 million (1.4% of sales), with adjusted EBITDA of $104 million (17.6% of sales).
• Adjusted net earnings per diluted share were $0.89, compared to $0.65 in the prior-year quarter.
• Company reaffirmed full-year 2026 guidance: revenue $2.31-2.37 billion, adjusted EBITDA $425-435 million, adjusted EPS $3.52-3.73, and free cash flow conversion of 25% or higher.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Full year 2025 net sales were $2.2 billion, up 7% reported and 6% organic; Reconstructive sales grew 10% reported and 8% organic, Prevention & Recovery grew 4% reported and organic.
• Full year 2025 net loss from continuing operations was $1,182 million, including a non-cash goodwill impairment charge of $1,050 million; adjusted EBITDA was $403 million.
• Fourth quarter 2025 net loss from continuing operations was $519 million, including a $501 million goodwill impairment charge; adjusted EBITDA was $112 million.
• 2026 guidance: revenue of $2.31-2.37 billion (4-6% organic growth), adjusted EBITDA of $425-435 million, and adjusted EPS of $3.52-$3.73.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Enovis Corporation's management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PST (7:30 p.m. EST).
• The presentation materials are attached as Exhibit 99.1 to the Form 8-K.
• The information is furnished under Item 7.01 Regulation FD Disclosure and is not incorporated by reference into any Enovis SEC filings.
• The report was signed by Bradley J. Tandy, Senior Vice President and Chief Legal Officer.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Laura Singleton, currently VP of Human Resources for the Reconstructive segment, is expected to be appointed as the new Senior VP and CHRO on April 3, 2026.
• Singleton joined Enovis in February 2019 via the DJO Global acquisition and previously held HR leadership roles at Toppan Photomasks, Ixia, and Millennium Laboratories.
• Lang and Enovis entered a retirement transition agreement dated December 10, 2025, covering her non-executive role from April 3, 2026 to April 3, 2027.
• During the transition period, Lang will receive her current base salary for six months, then a reduced salary (up to 50% less) for the remainder, while remaining eligible for company benefits and annual incentive plan.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• The amended credit agreement provides a $1.1 billion revolving credit facility and a $700.0 million term loan facility, with all maturities extended to December 8, 2030.
• Proceeds from the term loan facility were used to repay approximately $335.0 million of outstanding revolving borrowings, leaving $167.0 million outstanding under the revolver and $700.0 million under the term loan as of December 8, 2025.
• The amendment lowers the acquisition threshold for a temporary leverage ratio increase from $500.0 million to $300.0 million, and raises the cash offset limit for leverage calculations from $150.0 million to $400.0 million.
• Truist Bank, DNB Capital LLC, and Sumitomo Mitsui Banking Corporation joined as new lenders under the amended credit agreement.

1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• Daniel A. Pryor agreed to step down as executive officer of Enovis Corporation effective November 7, 2025, and will remain as an employee in an advisory role until March 31, 2026.
• Enovis and Pryor entered into a Separation and General Release Agreement dated November 14, 2025, under which he will provide transition services and continue to receive his current base salary and benefits until the Departure Date.
• Pryor remains eligible for a 2025 cash bonus under the annual incentive plan, and his equity awards will continue vesting through the Departure Date, but he will receive no further equity grants.
• After the Departure Date, subject to compliance, Pryor will receive cash payments equal to his annual base salary plus the greater of his target annual cash incentive or the average of the largest two annual cash incentives in the prior three years, plus a partial year bonus for 2026, 12 months of health benefits, and outplacement assistance capped at $75,000.